Gbolahan OB et al., 2022-05: Phase I trial of a curcumin-phosphatidylcholine complex with irinotecan (10 patients in dose escalation, 13 at 4 g/day): no significant change in irinotecan, SN-38 or SN-38G exposure and no increase in irinotecan toxicity.
PC did not significantly alter the plasma exposure and other PK properties of irinotecan and its metabolites. There was no apparent increase in the incidence of irinotecan-associated toxicities.
Abstract, Results
Gbolahan OB et al., 2022-05: Phase I trial of a curcumin-phosphatidylcholine complex with irinotecan (10 patients in dose escalation, 13 at 4 g/day): no significant change in irinotecan, SN-38 or SN-38G exposure and no increase in irinotecan toxicity. Directly tests the pharmacokinetic-interaction fear in humans at 4 g/day and does not find it; single-arm PK comparison within patients. Authors declare no competing interests; funder not stated. Comparator: same-patient irinotecan exposure with and without curcumin. Study type: uncontrolled series.
